Anti-BCMA CAR-T JNJ-4528 Hits 100% Response Rate in Heavily Pretreated Myeloma

Article

The BCMA-directed CAR T-cell therapy JNJ-4528 achieved a 100% overall response rate with early and deep responses in 29 patients with heavily pretreated relapsed/refractory myeloma.

Deepu Madduri, MD

Deepu Madduri, MD

Deepu Madduri, MD

The BCMA-directed CAR T-cell therapy JNJ-4528 achieved a 100% overall response rate (ORR) with early and deep responses in 29 patients with heavily pretreated relapsed/refractory myeloma, according to data from the phase Ib/II CARTITUDE-1 trial reported at the 2019 ASH Annual Meeting. 

The ORR comprised a 66% stringent complete response (CR) rate, 3% CR rate, 17% very good partial response (PR) rate, and 14% PR rate. The median follow-up was 6 months (range, 3-14), with  the median time to first response and median time to ≥CR both being 1 month. All but 2 patients remained progression-free at 6 months, and all 17 patients evaluable for minimal-residual disease (MRD) were MRD-negative. 

“Sixty-nine percent of the patients were in complete response, meaning that they had no evidence of myeloma cells in their bone marrow or in their blood. Eighty-six percent of the patients were in very good partial remission or better,” said lead study author Deepu Madduri, MD, Mount Sinai Medical Center.

Based on the CARTITUDE-1 findings, JNJ-4528 has received an FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory multiple myeloma. The designation will expedite the development and regulatory review of the anti-BCMA CAR-T treatment in this setting. 

Eligibility criteria for CARTITUDE-1 included measurable and progressive disease; an ECOG performance status of ≤1; at least 3 prior therapies or double-refractory status; and prior treatment with a proteasome inhibitor (PI), immunomodulatory drug (IMiD), and anti-CD38 therapy.

The median administered dose in the trial was 0.73 x 106 (0.52-0.89 x 106) CAR+ viable T cells/kg, and the study supported a recommended phase II dose of 0.75 x 106 CAR+ viable T cells/kg.

The median patient age was 60 years (range, 50-75), 25% (n = 7) of patients had a high-risk cytogenetic profile, and the median number of years since diagnosis was 6 (range, 2-16). Twenty-five (86%) patients had prior autologous transplantation and the median number of prior lines of therapy was 5 (range, 3-18). All 29 patients were triple-exposed (received a PI, IMiD, and anti—CD-38 therapy), with 86% (n = 25) being triple-refractory, and 72% (n = 21) of patients were penta-exposed (received ≥2 PIs, ≥2 IMiDs, and anti–CD-38 therapy), with 31% (n = 9) being penta-refractory.

Madduri noted that this heavily pretreated population has a high unmet medical need, with a median overall survival of less than 1 year. “We really need a product that we can give to these patients that will [induce] deep, sustained responses.” 

Commenting on the efficacy findings, Madduri said, “Every single patient expanded their T cells,” adding, “What we think makes this product unique is the preferential expansion of the CD8+ central memory phenotype. CD8 cells are used to kill myeloma cells [and] these central memory cells, we think, have a way of not getting exhausted as often and having sustained effector function.” 

Regarding safety, cytokine release syndrome (CRS) across all grades occurred in 93% (n = 27) of patients, with 2 patients experiencing grade ≥3 CRS. The median time to the onset of CRS was 7 days, with more than 90% of CRS starting at day 5 to 9.

“Most other [CAR-T] products have rapid expansion and you notice CRS happening within the first couple of days. But with this one, there’s slow expansion, causing the CRS to happen at closer to 7 days,” said Madduri. 

There was 1 dose-limiting toxicity of grade 4 CRS, which “converted to a grade 5 event, and the patient passed away from complications at day 99,” said Madduri. 

Neurotoxicity was uncommon, occurring at any grade in 3 patients, with 1 patient having grade ≥3 neurotoxicity.

Common (≥25%) hematologic AEs across all grades included neutropenia (93%), anemia (86%), thrombocytopenia (86%), leukopenia (52%), and lymphopenia (45%). Nonhematologic AEs reported in ≥25% of patients included increased AST (31%), increased ALT (28%), diarrhea (28%), and upper respiratory tract infection (28%).

Frequent grade ≥3 hematologic AEs included neutropenia (93%),  thrombocytopenia (69%), anemia (55%), leukopenia (52%), and lymphopenia (31%). Grade ≥3 nonhematologic AEs included increased AST (7%), increased ALT (3%), and diarrhea (3%). 

Madduri said the phase II portion of CARTITUDE-1 is fully enrolled and a phase III trial, CARTITUDE-4 (NCT04181827), has been initiated. CARTITUDE-4 is comparing JNJ-4528 with pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (PVd), or daratumumab (Darzalex), pomalidomide, and dexamethasone (DPd) in patients with relapsed and lenalidomide (Revlimid)-refractory multiple myeloma.

Madduri D, Usmani SZ,2 J, et al. Results from CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM). Presented at: 2019 ASH Annual Meeting; December 7-10, 2019; Orlando, FL. Abstract 577.

<<< View more from 2019 ASH Annual Meeting

The CARTITUDE-1 study design was informed by the earlier phase I LEGEND-2 study (NCT03090659), a first-in-human study that used an identical CAR construct in a slightly different patient population.&#8239;

Related Videos
John A. Charlson, MD
Judy Lieberman, MD, PhD, the endowed chair in cellular and molecular medicine at Boston Children’s Hospital
Omid Hamid, MD
Alexandra Gomez-Arteaga, MD
Brian Shaffer, MD
John Ligon, MD, an assistant professor in the department of pediatrics at the University of Florida College of Medicine
Judy Lieberman, MD, PhD, the endowed chair in cellular and molecular medicine at Boston Children’s Hospital
Alexandra Gomez Arteaga, MD
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin
Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute
Related Content
© 2024 MJH Life Sciences

All rights reserved.